Home Newsfeeds DA Davidson Maintains Buy on Comerica, Raises Price Target to $82

DA Davidson Maintains Buy on Comerica, Raises Price Target to $82

DA Davidson analyst Peter Winter maintains Comerica (NYSE:CMA) with a Buy and raises the price target from $80 to $82.

byBenzinga Newsdesk

January 20, 2023

1 minute read

DA Davidson analyst Peter Winter maintains Comerica (NYSE:CMA) with a Buy and raises the price target from $80 to $82.

Here’s How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today

By Benzinga Insights

September 15, 1:00 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.6% on an annualized basis…

VRTX

News

5 Value Stocks To Watch In The Basic Materials Sector

By Benzinga Insights

September 16, 11:10 AM

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

FSI

JMP Securities Upgrades Deciphera Pharmaceuticals to Market Outperform, Announces $23 Price Target

By Benzinga Newsdesk

August 5, 6:23 AM

JMP Securities analyst Reni Benjamin upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Perform to Market Outperform and announces $23 price target.

DCPH